Indication:

• Emjard™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM).

• Emjard™ is also indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Dosage & Administration:

The recommended dose of Emjard™ is 10 mg daily and is taken in the morning, with or without food. In patients tolerating Empagliflozin 10 mg, the dose may be increased to 25 mg once daily. In patients with Hypovolumia, correcting this condition before initiation of Empagliflozin 10 mg is recommended.

Preparation:

Emjard™ 10 Tablet: Each box contains 20's tablets in blister pack.

Emjard™ 25 Tablet: Each box contains 10's tablets in blister pack.